Myocardial Infarction Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Novartis, AstraZeneca, Recardio, Idorsia Pharma, Eli Lilly and Company, Boehringer

The Key Myocardial Infarction Companies in the market include - Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, and others.

DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Myocardial Infarction Market Report:

*
The Myocardial Infarction market size was valued approximately ~USD 21,750 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In August 2024, CellProthera announced a successful pre-investigational new drug (IND) meeting with the US Food and Drug Administration (FDA), bringing the company closer to launching a pivotal Phase III trial for its cell therapy targeting myocardial infarction. The France-based company stated that the FDA supported the trial design, which includes a two-year follow-up. The trial will assess the therapy's effectiveness in preventing future heart diseases.

*
In February 2024, Australian CSL announced the topline results from the Phase III AEGIS-II trial of CSL112 in patients after an acute myocardial infarction (MI). The results revealed that the drug did not achieve its primary endpoint of reducing the risk of major adverse cardiovascular events (MACE) within 90 days.

*
Estimates suggest that the United States will hold the largest share of the Myocardial Infarction Market, with a value of approximately ~USD 16,300 million in 2023, driven by a higher number of cases and relatively higher treatment costs.

*
In 2023, the total number of diagnosed prevalent cases of Myocardial Infarction across the 7MM was approximately 15.5 million, with expectations of growth during the forecast period.

*
In 2023, the United States had approximately 8 million diagnosed prevalent cases of Myocardial Infarction.

*
In 2023, the United States represented the largest share of the Myocardial Infarction prevalent population, accounting for approximately 55% of the 7MM. Meanwhile, EU4 and the UK contributed around 35%, and Japan made up about 10% of the total population share.

*
DelveInsight estimates indicate that in 2023, the United States had approximately 3.2 million cases of STEMI and 5 million cases of NSTEMI. The prevalence is expected to rise throughout the forecast period.

*
Key Myocardial Infarction Companies: Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, Idorsia Pharmaceuticals, and others

*
Key Myocardial Infarction Therapies: JARDIANCE (empagliflozin), Pelacarsen, FARXIGA(dapagliflozin), Dutogliptin, Selatogrel, abciximab, Empagliflozin, Aliskiren, Eplerenone, Fulacimstat (BAY1142524), Prochymal Registered , Angiomax (bivalirudin) anticoagulant, TNK-tPA, MCC-135, ATH3G10, RO4905417, Selatogrel, and others

*
The Myocardial Infarction epidemiology based on gender analyzed that the prevalence of myocardial infarction (MI) is more common among males as compared to females

*
The Myocardial Infarction market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myocardial Infarction pipeline products will significantly revolutionize the Myocardial Infarction market dynamics.

Myocardial Infarction Overview

Myocardial infarction, commonly known as a heart attack, occurs when the blood flow to a part of the heart muscle is blocked for an extended period. This blockage typically happens due to the rupture of a plaque buildup in one of the coronary arteries, which supply oxygen-rich blood to the heart muscle. Without adequate blood flow, the affected portion of the heart muscle begins to die.

Get a Free sample for the Myocardial Infarction Market Report:

https://www.delveinsight.com/report-store/myocardial-infarction-market [https://www.delveinsight.com/report-store/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myocardial Infarction Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myocardial Infarction Epidemiology Segmentation:

The Myocardial Infarction market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Myocardial Infarction

*
Prevalent Cases of Myocardial Infarction by severity

*
Gender-specific Prevalence of Myocardial Infarction

*
Diagnosed Cases of Episodic and Chronic Myocardial Infarction

Download the report to understand which factors are driving Myocardial Infarction epidemiology trends @ Myocardial Infarction Epidemiology Forecast [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myocardial Infarction Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myocardial Infarction market or expected to get launched during the study period. The analysis covers Myocardial Infarction market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myocardial Infarction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myocardial Infarction Therapies and Key Companies

*
JARDIANCE (empagliflozin): Boehringer Ingelheim/ Eli Lilly

*
Pelacarsen: Novartis

*
FARXIGA(dapagliflozin): AstraZeneca

*
Dutogliptin: Recardio

*
Selatogrel: Idorsia Pharmaceuticals

*
abciximab: Eli Lilly and Company

*
Empagliflozin: Boehringer Ingelheim

*
Aliskiren: Novartis

*
Eplerenone: Pfizer

*
Fulacimstat (BAY1142524): Bayer

*
Prochymal Registered : Mesoblast, Inc.

*
Angiomax (bivalirudin) anticoagulant: The Medicines Company

*
TNK-tPA: Boehringer Ingelheim

*
MCC-135: Mitsubishi Tanabe Pharma

*
ATH3G10: Athera Biotechnologies

*
RO4905417: Hoffmann-La Roche

*
Selatogrel: Idorsia Pharmaceuticals, and others

Discover more about therapies set to grab major Myocardial Infarction market share @ Myocardial Infarction Treatment Market [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myocardial Infarction Market Strengths

*
Increasing focus on the secondary preventive measure to avoid recurrent/new events, and lifestyle changes, along with the growing number of smokers and increasing cases of obesity, diabetes, hypertension, and others, are expected to foster the market growth of Myocardial Infarction

Myocardial Infarction Market Opportunities

*
Major cost drivers in the 7MM healthcare system are heart attacks and strokes. The volume of the MI market is incredibly large. The patient receives several therapies concurrently. The smallest patient share portion can provide pharmaceutical companies with options worth millions of dollars

Scope of the Myocardial Infarction Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Myocardial Infarction Companies: Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, Idorsia Pharmaceuticals, and others

*
Key Myocardial Infarction Therapies: JARDIANCE (empagliflozin), Pelacarsen, FARXIGA(dapagliflozin), Dutogliptin, Selatogrel, abciximab, Empagliflozin, Aliskiren, Eplerenone, Fulacimstat (BAY1142524), Prochymal Registered , Angiomax (bivalirudin) anticoagulant, TNK-tPA, MCC-135, ATH3G10, RO4905417, Selatogrel, and others

*
Myocardial Infarction Therapeutic Assessment: Myocardial Infarction current marketed and Myocardial Infarction emerging therapies

*
Myocardial Infarction Market Dynamics: Myocardial Infarction market drivers and Myocardial Infarction market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Myocardial Infarction Unmet Needs, KOL's views, Analyst's views, Myocardial Infarction Market Access and Reimbursement

To know more about Myocardial Infarction companies working in the treatment market, visit @ Myocardial Infarction Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Myocardial Infarction Market Report Introduction

2. Executive Summary for Myocardial Infarction

3. SWOT analysis of Myocardial Infarction

4. Myocardial Infarction Patient Share (%) Overview at a Glance

5. Myocardial Infarction Market Overview at a Glance

6. Myocardial Infarction Disease Background and Overview

7. Myocardial Infarction Epidemiology and Patient Population

8. Country-Specific Patient Population of Myocardial Infarction

9. Myocardial Infarction Current Treatment and Medical Practices

10. Myocardial Infarction Unmet Needs

11. Myocardial Infarction Emerging Therapies

12. Myocardial Infarction Market Outlook

13. Country-Wise Myocardial Infarction Market Analysis (2020-2034)

14. Myocardial Infarction Market Access and Reimbursement of Therapies

15. Myocardial Infarction Market Drivers

16. Myocardial Infarction Market Barriers

17. Myocardial Infarction Appendix

18. Myocardial Infarction Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myocardial-infarction-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-pfizer-novartis-astrazeneca-recardio-idorsia-pharma-eli-lilly-and-company-boehringer]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.